EZH2 and neoplasm: By targeting SLC31A1‐mediated copper influx and EZH2‐driven immunosuppression, our findings support repurposing copper chelators (e.g., TEPA) or developing SLC31A1 inhibitors to disrupt tumor‐intrinsic copper addiction.